Jul 31, 2019
Theravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
May 07, 2019
Theravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
Nov 12, 2018
Theravance Biopharma Highlights Expanded COPD Indication for Trelegy Ellipta in Europe
Sep 24, 2018
Theravance Biopharma Highlights Positive CHMP Opinion Supporting Expanded COPD Indication for Trelegy Ellipta in Europe
Apr 25, 2018
Theravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients
Apr 19, 2018
Theravance Biopharma Highlights Landmark IMPACT Study Published in NEJM Showing Significant Benefits of Trelegy Ellipta for COPD Patients
Nov 28, 2017
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy Ellipta
Oct 12, 2017
Global $41 Bn Respiratory Drugs Market to 2023 - Leading Players are GSK, AstraZeneca and Boehringer Ingelheim
Sep 20, 2017
Theravance Biopharma Highlights Positive Headline Results from IMPACT Study of Trelegy Ellipta Announced by GlaxoSmithKline and Innoviva
Sep 19, 2017
Theravance Biopharma Highlights Approval of Trelegy Ellipta (Closed Triple) as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US
Sep 18, 2017
Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US